669 results on '"Saul, Allan"'
Search Results
2. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM 197 conjugate vaccine
3. Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults
4. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
5. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics
6. Induction of Crossreactive Antibodies against the Plasmodium falciparum Variant Protein
7. High Diversity and Rapid Changeover of Expressed var Genes during the Acute Phase of Plasmodium falciparum Infections in Human Volunteers
8. A Recombinant Vaccine Expressed in the Milk of Transgenic Mice Protects Aotus Monkeys from a Lethal Challenge with Plasmodium falciparum
9. Efficient Autotransporter-Mediated Extracellular Secretion of a Heterologous Recombinant Protein by Escherichia coli
10. The transfer and decay of maternal antibody against Shigella sonnei in a longitudinal cohort of Vietnamese infants
11. Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) reveals highly pure preparations
12. Design of a Phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine
13. Simplified low-cost production of O-antigen from Salmonella Typhimurium Generalized Modules for Membrane Antigens (GMMA)
14. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)
15. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials
16. Vaccines against poverty
17. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X
18. Comparison of Colorimetric Assays with Quantitative Amino Acid Analysis for Protein Quantification of Generalized Modules for Membrane Antigens (GMMA)
19. Author Correction: Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics
20. Additional file 1 of The impact of three progressively introduced interventions on second wave daily COVID-19 case numbers in Melbourne, Australia
21. Malaria Vaccines Based on the Plasmodium falciparum Merozoite Surface Protein 3: Should We Avoid Amino Acid Sequence Polymorphisms or Embrace Them?
22. Efficient autotransporter-mediated extracellular secretion of a heterologous recombinant protein by Escherichia coli
23. Sustained High-Titer Antibody Responses Induced by Conjugating a Malarial Vaccine Candidate to Outer-Membrane Protein Complex
24. A Recombinant Blood-Stage Malaria Vaccine Reduces Plasmodium falciparum Density and Exerts Selective Pressure on Parasite Populations in a Phase 1-2b Trial in Papua New Guinea
25. Merozoite Surface Protein 3 and Protection against Malaria in Aotus nancymai Monkeys
26. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes
27. Novel Simple Conjugation Chemistries for Decoration of GMMA with Heterologous Antigens
28. Diagnosis of malaria in a remote area of the Philippines: comparison of techniques and their acceptance by health workers and the community
29. Transport of an M r ∼ 300,000 Plasmodium falciparum Protein (Pf EMP 2) from the Intraerythrocytic Asexual Parasite to the Cytoplasmic Face of the Host Cell Membrane
30. Decreased Membrane Deformability in Melanesian Ovalocytes from Papua New Guinea
31. A Protective Monoclonal Antibody Recognizes a Linear Epitope in the Precursor to the Major Merozoite Antigens of Plasmodium chabaudi adami
32. Ovalocytic Erythrocytes from Melanesians are Resistant to Invasion by Malaria Parasites in Culture
33. The introduction of a mandatory mask policy was associated with significantly reduced COVID-19 cases in a major metropolitan city
34. The impact of three progressively introduced interventions on second wave daily COVID-19 case numbers in Melbourne, Australia
35. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders
36. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines
37. Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension
38. Reanalysis of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine data fails to find any increased efficacy following the boost: Implications for vaccination policy and our understanding of the mode of action
39. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen
40. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: A strategy for enhancing immunogenicity of malaria vaccine candidates
41. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials
42. Efficacy, Safety, and Immunogenicity of the Shigella sonnei1790GAHB GMMA Candidate Vaccine: Results from a Phase 2b Randomized, Placebo-Controlled Challenge Study in Adults
43. Progress and challenges for malaria vaccines
44. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel ®, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide
45. Malaria transmission-blocking vaccines—how can their development be supported?
46. Using SDS-PAGE and Scanning Laser Densitometry to Measure Yield and Degradation of Proteins
47. Impact of Victoria’s Stage 3 lockdown on COVID‐19 case numbers
48. Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus
49. GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines
50. Intra-Laboratory Evaluation of Luminescence Based High-Throughput Serum Bactericidal Assay (L-SBA) to Determine Bactericidal Activity of Human Sera against Shigella
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.